Allogeneic CTX130 CAR T cells avoid fratricide by CRISPR-mediated CD70 knockout and have demonstrated a promising objective response rate in patients with heavily pre-treated T-cell lymphoma during a Phase 1 clinical study. Here, CD70 is linked to T-cell non-Hodgkin lymphoma.